Document Detail


Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
MedLine Citation:
PMID:  20567995     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Aim: We have examined the cellular action of SN 28049 (N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide), a DNA binding drug with curative activity against the Colon 38 transplantable murine carcinoma, on human tumour cells. Its action has been compared with that of two topoisomerase II-targetted drugs, etoposide and doxorubicin. Methods: The NZM3 melanoma and HCT116 colon carcinoma cell lines, each expressing wild-type p53, were cultured and responses were compared by flow cytometry, electrophoresis, microscopy, and growth of tumour xenografts. Results: Responses of NZM3 cells to all three drugs, as measured by histone H2AX γ-phosphorylation, induction of the p53 pathway and cell cycle arrest, were comparable and typical of those of topoisomerase II poisons. Xenografts of NZM3 cells responded to SN 28049 with a tumour growth delay of 16 days. In contrast, HCT116 cells had an attenuated DNA damage response to the drugs and SN 28049 had no in vivo activity, consistent with low topoisomerase II activity. However, SN 28049 inhibited HCT116 cell growth in vitro and activated the p53 pathway to induce a state with G(2)/M-phase DNA content, low mitotic index and a high proportion of binucleate cells. Treated cells expressed cyclin E and the senescence marker β-galactosidase but showed low expression of cyclin B and survivin. In comparison, etoposide caused little p53 expression or cycle arrest, and doxorubicin had an intermediate effect. Conclusion: The action of SN 28049 in NZM3 cells is typical of a topoisomerase II poison, but the low topoisomerase IIα activity of HCT116 cells allowed the detection of a second antiproliferative action of SN 28049 in which cells undergo post-mitotic cycle arrest and induction of p53.
Authors:
Catherine J Drummond; Graeme J Finlay; Laura Broome; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Related Documents :
9266965 - Intercellular induction of apoptosis in transformed cells does not depend on p53.
10702305 - P53 induces apoptosis by caspase activation through mitochondrial cytochrome c release.
18440285 - Sustained activation of p53 in confluent nucleotide excision repair-deficient cells res...
20519945 - P53 in cytoplasm exerts 3'→5' exonuclease activity with dsrna.
10369205 - Assisted reproduction for testicular failure: management of germ cell maturation arrest.
6156175 - Surface functions during mitosis. ii. quantitation of pinocytosis and kinetic character...
Publication Detail:
Type:  Journal Article     Date:  2010-06-22
Journal Detail:
Title:  Investigational new drugs     Volume:  29     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-08-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1102-10     Citation Subset:  IM    
Affiliation:
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand, cath.drummond@newcastle.ac.uk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ultraviolet recall dermatitis reaction with sorafenib.
Next Document:  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using...